Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 7/20 | 0.83 |
| ▸ | PAK1 | Q13153 | 5/20 | 0.67 |
| ▸ | JAK3 | P52333 | 6/20 | 0.65 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | BLK | P51451 | 1/20 | 0.58 |
| ▸ | BMX | P51813 | 1/20 | 0.58 |
| ▸ | CDK7 | P50613 | 1/20 | 0.55 |
| ▸ | CCNH | P51946 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15638700 | 0.91 | BTK (1.00) | BTKPAK1JAK3EGFRJAK2 | |
| SCHEMBL10127962 | 0.89 | BTK (1.00) | BTKPAK1JAK3EGFRJAK2 | |
| SCHEMBL17062815 | 0.89 | BTK (0.87) | BTKPAK1JAK3EGFRJAK2 | |
| SCHEMBL17359449 | 0.87 | BTK (0.72) | BTKPAK1JAK3EGFRJAK2 | |
| SCHEMBL17359459 | 0.87 | BTK (0.74) | BTKPAK1JAK3EGFRJAK2 | |
| SCHEMBL17359435 | 0.85 | BTK (0.69) | BTKPAK1JAK3EGFRJAK2 | |
| SCHEMBL17071407 | 0.84 | BTK (0.88) | BTKJAK3EGFRJAK2CDK7 | |
| SCHEMBL17359437 | 0.84 | BTK (0.60) | BTKPAK1JAK3EGFRJAK2 | |
| SCHEMBL17359453 | 0.84 | BTK (0.80) | BTKPAK1JAK3EGFRJAK2 | |
| SCHEMBL17359436 | 0.83 | BTK (0.66) | BTKPAK1JAK3EGFRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903971-B1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIV UTAH RES FOUND (US) | 2019-06-12 | — | — | EP | disclosed |
| US-9296703-B2 | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150368208-A1 | Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors | UNIVERSITY OF UTAH | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368208-A1 | Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors | BTK, SYK, LYN | BTK 1/4885PAK1 204/4885JAK3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.